Skip to main content
Oryzon
  • Company
    • Overview
    • Strategy
    • Team
  • Epigenetics
    • Epigenetics
    • LSD1
  • Programs
    • Pipeline
    • Iadademstat
    • Vafidemstat
    • Collaborations
    • Publications
  • Patients
    • Clinical Trials
  • Investors
    • Share Information
      • Share Performance
      • Shares and Capital Structure
      • Dividends
      • Share Issues
      • Takeover Bids
      • Shareholdings
    • Financial Information
      • Financial Results and Accounts
      • Public Periodic Information
      • Average supplier payment period
    • CNMV Filings
    • Analyst Coverage
    • Corporate Governance
      • General Shareholders Meeting
      • Board of Directors
      • Board Committees
      • Shareholder Agreements
      • Annual Corporate Governance Reports
      • Annual Director Remuneration Reports
    • Corporate Social Responsibility
  • News & Events
    • Press releases
    • Events
  • Contact
    • Contact
    • Email Alerts
    • Join us
    • English
    • Español

Pioneering
personalized medicine
in epigenetics

Oryzon now

12 May 2025

ORYZON reports financial results and corporate update for quarter ended March 31, 2025

Read more
27 May 2025

ORYZON to provide corporate progress updates at several events in May-June

Read more
26 May 2025

ORDINARY GENERAL SHAREHOLDERS’ MEETING 2025
June 27th, 2025 at 13:00 hours on 2nd call

Read more
12 May 2025

ORYZON reports financial results and corporate update for quarter ended March 31, 2025

Read more
27 May 2025

ORYZON to provide corporate progress updates at several events in May-June

Read more
26 May 2025

ORDINARY GENERAL SHAREHOLDERS’ MEETING 2025
June 27th, 2025 at 13:00 hours on 2nd call

Read more
12 May 2025

ORYZON reports financial results and corporate update for quarter ended March 31, 2025

Read more

ORYZON is a public clinical stage biopharmaceutical company developing innovative epigenetic personalized medicines for patients with cancer and CNS disorders

About us
Epigenetics

Epigenetics is a regulatory system that controls gene expression without affecting the makeup of the genes themselves. Regulation of gene transcription and translation are key biological determinants for cellular differentiation and function, and transcriptional imbalances play a significant pathogenic role in a number of human diseases.

More info
Therapeutic programs

ORYZON is a clinical stage biopharmaceutical company that leverages epigenetics to discover and develop innovative personalized therapeutics for patients with cancers and CNS disorders. We are able to identify and validate biomarkers and therapeutic targets through our epigenetic platform and translate them into advanced and personalized therapies.

More info
Latest News
  • 27 May 2025

    ORYZON to provide corporate progress updates at several events in May-June

    • Read more about ORYZON to provide corporate progress updates at several events in May-June
  • 12 May 2025

    ORYZON reports financial results and corporate update for quarter ended March 31, 2025

    • Read more about ORYZON reports financial results and corporate update for quarter ended March 31, 2025
  • 8 May 2025

    ORYZON awarded 13.26 million € through the first Important Project of Common European Interest (IPCEI) in the health sector (Med4Cure project)

    • Read more about ORYZON awarded 13.26 million € through the first Important Project of Common European Interest (IPCEI) in the health sector (Med4Cure project)
All News
Upcoming events
  • 27-29 May 2025

    Foro MedCap 2025

    Madrid Stock Exchange Palace

    Madrid

    Spain

    • More details about Foro MedCap 2025
  • 16-19 June 2025

    BIO International Convention 2025

    Boston Convention & Exhibition Center, Boston

    MA

    United States

    • More details about BIO International Convention 2025
  • 23-24 June 2025

    Discovery and Development Europe 2025

    Congress Center

    Basel

    Switzerland

    • More details about Discovery and Development Europe 2025
All Events
Logo Oryzon
  • Company
    • Overview
    • Strategy
    • Team
  • Epigenetics
    • Epigenetics
    • LSD1
  • Programs
    • Pipeline
    • Iadademstat
    • Vafidemstat
    • Collaborations
    • Publications
  • Patients
    • Clinical Trials
  • Investors
    • Share Information
    • Financial Information
    • CNMV Filings
    • Analyst Coverage
    • Corporate Governance
    • Corporate Social Responsibility
  • News & Events
    • Press releases
    • Events
  • Contact
    • Contact
    • Email Alerts
    • Join us
  • © Oryzon Genomics, S.A. - All Rights Reserved

    • Legal
    • Privacy Policy
    • Cookie Policy
    • Ethics Channel

We use our own and third-party cookies for analytical purposes. You can obtain more information in our Cookies Policy. Likewise, you can accept all our own and third-party cookies that we use by pressing the “Accept Cookies” button, reject all cookies by pressing the “Reject Cookies” button or access the configuration panel by pressing the “Configure” button.

Privacy Summary

This Website uses cookies that store and retrieve information when you are browsing. In general, these technologies can serve very different purposes, such as recognizing you as a user, obtaining information about your browsing habits or personalizing the way in which content is displayed. Click the headers for each cookie type to change our default settings:

These are those that allow the user to navigate through a website, platform or application and the use of the different options or services that exist in it. These cookies do not store any personal information.
Analytical cookies are used to understand how visitors interact with the website. These cookies help to provide information about metrics, number of visitors, bounce rate, traffic source, etc.
Back to top